MIG blockade has been described as a prospective therapeutic target for Crohn’s disease, and serum MIG levels represent the activity of the disease (101); in patients with rheumatoid arthritis, the expression of MIG is observed in the serum, synovial fluid, and synovial tissues (102). This evidence concerns the gene CXCL9 and rheumatoid arthritis.